<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Control of blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels and restoration of pancreatic islet function are among the goals of physicians seeking to improve outcomes in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="1" pm="."><plain>A growing body of evidence supports the use of incretins to achieve these goals, and current guidelines recommend earlier and more frequent use of these agents </plain></SENT>
<SENT sid="2" pm="."><plain>However, in patients with T2DM, treatment paradigms should always be individualized </plain></SENT>
<SENT sid="3" pm="."><plain>The author discusses issues for physicians to consider when adjusting T2DM therapy, including patient comorbidities, <z:chebi fb="105" ids="17234">glucose</z:chebi> control patterns, and potential adverse effects </plain></SENT>
<SENT sid="4" pm="."><plain>The importance of patient education and practical points for initiating a glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> are also reviewed </plain></SENT>
</text></document>